Dear Editors,

 {#apt15886-sec-0001}

We read with great interest the letter by Nathwani et al[^1^](#apt15886-bib-0001){ref-type="ref"}, commenting on our article on COVID‐19 and liver disease[^2^](#apt15886-bib-0002){ref-type="ref"}. They reported their experience in managing abnormal liver function tests during SARS‐CoV‐2 infection and the impact of COVID‐19 in patients with underlying chronic liver disease. The authors concluded that mild serum elevations of aminotransferases were associated with more severe disease but not increased mortality. Additionally, they also reported that cirrhosis predisposes to increase in length of stay, although the overall mortality was similar to those without liver disease.

We agree that patients with cirrhosis would be of major concern~~s~~ because of their immune dysfunction, resulting in a high risk of infection, prolonged hospitalisations and worse outcomes. However, in the series reported by Nathwani et al, liver cirrhosis did not predispose to increase in mortality, which is different from what has been reported in other recent publications. It should be noted that whether pharmacological therapy was used during hospitalisation was not reported; for example targeted anti‐viral therapy, which is known to influence the outcomes of cirrhotic patients. In addition, the cause of death, whether liver related or not, was also not reported.

A recent systematic review and meta‐analysis showed an increased risk of severity and mortality in COVID‐19 patients with liver diseases[^3^](#apt15886-bib-0003){ref-type="ref"}. Moreover, Moon et al analysed 152 cases of laboratory‐confirmed SARS‐CoV‐2 infection in patients with chronic liver disease and reported that liver cirrhosis was strongly associated with COVID‐19‐related mortality[^4^](#apt15886-bib-0004){ref-type="ref"}. Severe outcomes correlated strongly with baseline Child‐Turcotte‐Pugh (CTP) class and model for end‐stage liver disease score. Indeed, CTP‐B and CTP‐C cirrhosis remained significant predictors of mortality in these patients. Finally, a multicentre study from the United States found that the relative risk (RR) of mortality was markedly higher not only in patients with pre‐existing liver disease but especially in those with cirrhosis (RR 2.8 vs 4.6)[^5^](#apt15886-bib-0005){ref-type="ref"}.

The care of cirrhotic patients remains a challenge in COVID‐19 pandemic. The data reported by Nathwani et al are a valuable addition to the reported experience with COVID‐19 in liver cirrhosis[^1^](#apt15886-bib-0001){ref-type="ref"}. Protective measures aimed at preventing infection with SARS‐CoV‐2 and precautions to guarantee the best treatment to avoid hepatic decompensation are of utmost importance[^6^](#apt15886-bib-0006){ref-type="ref"}, [^7^](#apt15886-bib-0007){ref-type="ref"}. Patients with cirrhosis testing positive for SARS‐CoV‐2 must be admitted for inpatient care if another poor prognostic factor was present, such as cardiovascular diseases, CTP B/C, hepatocellular carcinoma or liver transplantation. It is also recommended to testing for SARS‐CoV‐2 in patients with acute decompensation.

In conclusion, it is essential an immediate contact after the appearance of signs or symptoms compatible with COVID‐19 or decompensated cirrhosis for urgent referral and management. Additionally, more intensive surveillance and individually tailored therapeutic approaches are needed for cirrhotic patients with SARS‐CoV‐2 infection. Further research identifying interventions to reduce poor outcomes in these patients is required.
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